R

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Vice President - Global Manufacturing

Full-TimePosted on 10/18/2026
$290k - $340k+ Annual performance bonus + Stock options
Expert
Bachelor's
Remote in USA+1 moreMore locations: Redwood City, CA, USA
RemoteRemote within the US; domestic and international travel up to 50% is required.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A B.S. in Engineering, Life Sciences, or a related field is required; an advanced degree is preferred.
  • At least 15 years of biologics manufacturing experience within biotech or biopharmaceutical organizations, including 5–7+ years in senior leadership with demonstrated executive experience at Vice President or Executive Director level.
  • Hands-on experience building an external manufacturing function, its systems, procedures, and team in a late-phase to commercial biotech context.
  • Expertise in monoclonal antibody Drug Substance and aseptic fill-finish Drug Product manufacturing.
  • Commercial launch experience, including PPQ, BLA/MAA submission support, pre-approval inspection readiness, and transition to commercial supply.
  • Track record managing executive relationships with CDMOs at Site Head level and above-site, resulting in resolution of capacity, capability, and reliability issues.
  • Experience establishing manufacturing redundancy, second-source, or dual-site supply for biologics.
  • Experience negotiating master services, supply, and capacity reservation agreements.
  • Ability to lead through influence, act with agility, lead problem solving, and drive robust solutions; communication demonstrated at all organizational levels.
  • Ability to meet morning, evening, and/or weekend commitments as needed because the team spans the US and service providers are offshore.
  • Ability to travel domestically and internationally up to 50%.
Responsibilities
  • Design, develop, and implement the transition from clinically oriented manufacturing operations to a robust, reliable, and redundant commercial manufacturing network supporting global markets, while maintaining agility and installing the rigor needed to meet market demand through external service providers.
  • Oversee all externalized manufacturing from cell line through Drug Product, including cell line development, cell bank manufacture and maintenance, Drug Substance manufacture, and aseptic fill-finish Drug Product manufacture across qualified global service providers.
  • Oversee storage and depot facilities supporting the manufacturing network, including cell banks, Drug Substance, and Drug Product; Drug Product accountability transfers to Global Supply Chain upon shipment from the manufacturing site.
  • Oversee manufacturing elements of the Plan of Record, including Drug Substance and Drug Product supporting two advanced P3 programs preparing for potential global launches.
  • Own the Manufacturing Plan as an output of the S&OP process led by Global Supply Chain; translate the consensus supply plan into Drug Substance and Drug Product campaign schedules, capacity reservations, slot commitments, and critical materials plans, and provide capacity, constraint, and risk input to S&OP.
  • Build and sustain executive relationships with service providers at Site Head and above-site levels to influence priority, capacity, and investment and resolve capability, reliability, and readiness issues.
  • Apply tiered governance with service providers at operational, site leadership, and executive steering levels to ensure clear understanding of work, costs, risks, and deliverables, with defined escalation paths.
  • Develop and execute the global manufacturing network strategy, including redundancy, second-source and dual-site strategies for Drug Substance and Drug Product, business continuity planning, and long-term manufacturing solutions aligned with corporate strategy and evolving goals.
  • Establish and manage service provider performance against Right First Time and On Time In Full expectations through defined key performance indicators, routine performance reviews, and corrective action.
  • Identify and mitigate risks to Drug Substance and Drug Product manufacture and supply; assess risks within the role's scope, implement mitigation plans, and escalate as appropriate.
  • Build and lead a Manufacturing Technical team supporting routine manufacture, including person-in-plant oversight, campaign technical monitoring, batch record and process performance review, and technical leadership of deviation and investigation resolution at service providers.
  • Build redundant, reliable capability across the manufacturing platform and enable site transfers through registration by establishing service provider relationships and leading program, contract, and deliverable management; partner with the MSAT team within Quality on technical specifications, characterization, qualification, validation, and Module 3 authorship.
  • Lead cross-functional collaboration among Quality, MSAT, and Technical Operations Leadership to resolve deviations, investigations, and CAPAs and support reliable, on-time supply.
  • Support global submissions and pre-approval inspection readiness at service providers with Quality and Regulatory teams.
  • Collaborate as part of the broader Technical Operations Leadership team.
  • Build, lead, manage, and develop a high-performance, phase-appropriate team, including external manufacturing leads for Drug Substance and Drug Product, cell line and cell bank management, manufacturing planning, and the Manufacturing Technical team.
  • Build phase-appropriate manufacturing systems, procedures, and governance for service provider oversight, manufacturing planning, performance management, and executive escalation.
  • Work with the Head of Quality to integrate manufacturing with Quality activities, including batch disposition support, deviation and change control, supplier qualification and audits, and inspection readiness; support registrational compliance evaluation and ongoing drug release.
  • Partner with the Vice President, Global Supply Chain to ensure seamless Drug Product handoff from the manufacturing network to global supply chain and alignment between the Manufacturing Plan and FDP supply plan.
  • Manage financial aspects of manufacture, including contracts, budgeting, forecasting, long-range planning, capacity commitments, and Cost of Goods for Drug Substance and Drug Product.
  • Lead service provider relationship development and contracting, including master services, supply, capacity reservation, and technical agreements; ensure agreements are negotiated to meet near- and long-term needs cost-effectively in coordination with Legal, Finance, Quality, and functional heads.
  • Coordinate selection and oversight of service providers and suppliers of critical raw materials, consumables, and primary components for Drug Substance and Drug Product.
  • Work cross-functionally to identify product lifecycle needs, such as scale, presentation, and line changes, and enable feasibility and implementation with MSAT, product, and corporate strategy.
  • Review technical documentation and summaries for sound rationale, regulatory and approval conformance, and effectiveness in achieving their intended purpose.
Desired Qualifications
  • Rare Disease experience.
  • Technical awareness of cell line development.
  • Experience working with multiple CDMO networks across the US, EU, and Asia.
  • Experience communicating manufacturing risk and strategy at board and executive levels.

About the company

Rezolute Bio develops therapies for rare diseases, aiming to address unmet needs in both pediatric and adult patients. Its lead candidate, RZ358, is a human monoclonal antibody in late-stage trials for congenital hyperinsulinism and works by binding to and inhibiting insulin to reduce hypoglycemic events. The company also pursues RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Its goal is to bring approved therapies to patients by advancing late-stage programs toward commercialization and building a portfolio focused on rare diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Louisville, Kentucky

Founded

2010

Get referred to Rezolute Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PES 2026 analyses showed CGM hypoglycemia reductions above 50% versus placebo.
  • FDA accepted tumor HI development streamlining in September 2025, with topline data expected 2H 2026.
  • Cash and investments reached $120.3 million on March 31, 2026, supporting runway.

What critics are saying

  • SunRIZE missed primary and key secondary endpoints in December 2025, damaging approval odds.
  • FDA requested broader sunRIZE and extension datasets on March 17, 2026, delaying filing.
  • A December 2025 layoff cut 29 employees after the setback, signaling fragile execution.

What makes Rezolute Bio unique

  • Ersodetug targets insulin receptor signaling, addressing congenital and tumor hyperinsulinism downstream.
  • FDA granted Breakthrough Therapy Designation for congenital HI on January 7, 2025.
  • Rezolute paired ersodetug with commercial hires from Ultragenyx and Cytokinetics in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Disability Insurance
  • Life Insurance
  • Paid Holidays
  • Paid Vacation
  • 401(k) Plan Match
  • Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

1%

2 year growth

-1%
Africa Business Watch
Jul 21st, 2026
Rezolute to participate in the BTIG Virtual Biotechnology Conference.

Rezolute to participate in the BTIG Virtual Biotechnology Conference. REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The Manila Times
Apr 21st, 2026
Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting.

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting. By GlobeNewswire April 21, 2026 Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting being held April 30-May 3, 2026, in San Francisco, CA. In addition to the previously reported topline results, the presentation will also include results from pre-specified and post-hoc sunRIZE analyses, which the Company believes continue to demonstrate target engagement and the therapeutic benefit of ersodetug. Presentation Title: Top-Line Results From a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Format: Oral presentation Presenter: Diva D. De León-Crutchlow, MD, MSCE Session Date and Time: Friday, May 1, 2026, from 8:15 a.m. - 9:15 a.m. PT Session Title: Oral Abstracts #1 About sunRIZE The Phase 3 sunRIZE study (RZ358-301) was a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who were experiencing continued hypoglycemia on currently available standard of care (SOC). Eligible participants were randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug was administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period. Following the pivotal treatment phase of the study, participants could roll-over into an optional open-label extension phase to continue to receive ersodetug. The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients. The primary and key secondary efficacy endpoints in the study were the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment. About Ersodetug Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim 336-608-9706

The Manila Times
Mar 4th, 2026
Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute to participate in the Citizens Life Sciences Conference. By GlobeNewswire March 4, 2026 REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim powered by 336-608-9706

Rezolute, Inc.
Feb 4th, 2026
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. February 04, 2026 7:00 am EST Download as PDF REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Released February 4, 2026

Fierce Pharma
Aug 21st, 2025
Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch

Karnawat joins Rezolute from Cytokinetics, where he spent just over a year as vice president of global value, access and distribution.